Skip to Content
Merck
CN
  • Characterization of core fucosylation via sequential enzymatic treatments of intact glycopeptides and mass spectrometry analysis.

Characterization of core fucosylation via sequential enzymatic treatments of intact glycopeptides and mass spectrometry analysis.

Nature communications (2022-07-08)
Liwei Cao, T Mamie Lih, Yingwei Hu, Michael Schnaubelt, Shao-Yung Chen, Yangying Zhou, Chuanyu Guo, Mingming Dong, Weiming Yang, Rodrigo Vargas Eguez, Lijun Chen, David J Clark, Akrit Sodhi, Qing Kay Li, Hui Zhang
ABSTRACT

Core fucosylation of N-linked glycoproteins has been linked to the functions of glycoproteins in physiological and pathological processes. However, quantitative characterization of core fucosylation remains challenging due to the complexity and heterogeneity of N-linked glycosylation. Here we report a mass spectrometry-based method that employs sequential treatment of intact glycopeptides with enzymes (STAGE) to analyze site-specific core fucosylation of glycoproteins. The STAGE method utilizes Endo F3 followed by PNGase F treatment to generate mass signatures for glycosites that are formerly modified by core fucosylated N-linked glycans. We benchmark the STAGE method and use it to characterize site specific core fucosylation of glycoproteins from human hepatocellular carcinoma and pancreatic ductal adenocarcinoma, resulting in the identification of 1130 and 782 core fucosylated glycosites, respectively. These results indicate that our STAGE method enables quantitative characterization of core fucosylation events from complex protein mixtures, which may benefit our understanding of core fucosylation functions in various diseases.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Endoglycosidase F3 from Elizabethkingia miricola, recombinant, expressed in E. coli, 30 U/mg